Topiramate-phentermine combinations reduce cocaine self-administration in humans
Copyright © 2020. Published by Elsevier B.V..
RATIONALE: Cocaine use disorder is an unrelenting public health concern. Despite nearly four decades of research, an FDA approved medication is not yet available.
OBJECTIVES: The objective of this human laboratory study was to demonstrate the initial efficacy, safety and tolerability of topiramate-phentermine combinations for cocaine use disorder.
METHODS: Thirty-one (31) participants with cocaine use disorder completed this mixed-model inpatient laboratory study. Participants were maintained on topiramate (0 [N = 11], 50 [N = 9] or 100 [N = 11] mg/day). Each topiramate group was concurrently maintained on phentermine (0, 15, 30 mg). Drug self-administration, subjective responses and cardiovascular effects following acute doses of intranasal cocaine (0, 40, 80 mg) were determined during separate experimental sessions after at least seven (7) days of maintenance on each condition.
RESULTS: The three groups of participants were well matched demographically and generally did not differ significantly in their responses to a range of doses of intranasal cocaine (0, 10, 20, 40, 80 mg) during a medical safety session. Maintenance on topiramate and phentermine alone significantly decreased cocaine self-administration although these effects were modest in magnitude. Combining topiramate and phentermine robustly decreased cocaine self-administration. Topiramate and phentermine were well tolerated alone and combined, as well as in conjunction with cocaine.
CONCLUSIONS: The results of the present study support advancing topiramate-phentermine combinations as a putative pharmacotherapeutic for cocaine use disorder.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:218 |
|---|---|
| Enthalten in: |
Drug and alcohol dependence - 218(2021) vom: 01. Jan., Seite 108413 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rush, Craig R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0H73WJJ391 |
|---|
| Anmerkungen: |
Date Completed 01.06.2021 Date Revised 01.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.drugalcdep.2020.108413 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31856484X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31856484X | ||
| 003 | DE-627 | ||
| 005 | 20231225165619.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drugalcdep.2020.108413 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1061.xml |
| 035 | |a (DE-627)NLM31856484X | ||
| 035 | |a (NLM)33290875 | ||
| 035 | |a (PII)S0376-8716(20)30578-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rush, Craig R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Topiramate-phentermine combinations reduce cocaine self-administration in humans |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.06.2021 | ||
| 500 | |a Date Revised 01.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier B.V. | ||
| 520 | |a RATIONALE: Cocaine use disorder is an unrelenting public health concern. Despite nearly four decades of research, an FDA approved medication is not yet available | ||
| 520 | |a OBJECTIVES: The objective of this human laboratory study was to demonstrate the initial efficacy, safety and tolerability of topiramate-phentermine combinations for cocaine use disorder | ||
| 520 | |a METHODS: Thirty-one (31) participants with cocaine use disorder completed this mixed-model inpatient laboratory study. Participants were maintained on topiramate (0 [N = 11], 50 [N = 9] or 100 [N = 11] mg/day). Each topiramate group was concurrently maintained on phentermine (0, 15, 30 mg). Drug self-administration, subjective responses and cardiovascular effects following acute doses of intranasal cocaine (0, 40, 80 mg) were determined during separate experimental sessions after at least seven (7) days of maintenance on each condition | ||
| 520 | |a RESULTS: The three groups of participants were well matched demographically and generally did not differ significantly in their responses to a range of doses of intranasal cocaine (0, 10, 20, 40, 80 mg) during a medical safety session. Maintenance on topiramate and phentermine alone significantly decreased cocaine self-administration although these effects were modest in magnitude. Combining topiramate and phentermine robustly decreased cocaine self-administration. Topiramate and phentermine were well tolerated alone and combined, as well as in conjunction with cocaine | ||
| 520 | |a CONCLUSIONS: The results of the present study support advancing topiramate-phentermine combinations as a putative pharmacotherapeutic for cocaine use disorder | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Cocaine | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Pharmacotherapy | |
| 650 | 4 | |a Phentermine | |
| 650 | 4 | |a Self-administration | |
| 650 | 4 | |a Topiramate | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Topiramate |2 NLM | |
| 650 | 7 | |a 0H73WJJ391 |2 NLM | |
| 650 | 7 | |a Fructose |2 NLM | |
| 650 | 7 | |a 30237-26-4 |2 NLM | |
| 650 | 7 | |a Phentermine |2 NLM | |
| 650 | 7 | |a C045TQL4WP |2 NLM | |
| 650 | 7 | |a Cocaine |2 NLM | |
| 650 | 7 | |a I5Y540LHVR |2 NLM | |
| 700 | 1 | |a Stoops, William W |e verfasserin |4 aut | |
| 700 | 1 | |a Lile, Joshua A |e verfasserin |4 aut | |
| 700 | 1 | |a Alcorn, Joseph L |c 3rd |e verfasserin |4 aut | |
| 700 | 1 | |a Bolin, B Levi |e verfasserin |4 aut | |
| 700 | 1 | |a Reynolds, Anna R |e verfasserin |4 aut | |
| 700 | 1 | |a Hays, Lon R |e verfasserin |4 aut | |
| 700 | 1 | |a Rayapati, Abner O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug and alcohol dependence |d 1980 |g 218(2021) vom: 01. Jan., Seite 108413 |w (DE-627)NLM000147869 |x 1879-0046 |7 nnns |
| 773 | 1 | 8 | |g volume:218 |g year:2021 |g day:01 |g month:01 |g pages:108413 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.drugalcdep.2020.108413 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 218 |j 2021 |b 01 |c 01 |h 108413 | ||